• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Transplant . Predictors and Outcomes of Respiratory Failure among Lung Transplant Patients with COVID-19

tetano

Editor, Senior Moderator
Clin Transplant


. 2021 Nov 18;e14540.
doi: 10.1111/ctr.14540. Online ahead of print.
Predictors and Outcomes of Respiratory Failure among Lung Transplant Patients with COVID-19


Adrian Lawrence[SUP] 1 [/SUP], Luke D Mahan[SUP] 1 [/SUP], Manish R Mohanka[SUP] 1 [/SUP], Srinivas Bollineni[SUP] 1 [/SUP], Vaidehi Kaza[SUP] 1 [/SUP], Ricardo M La Hoz[SUP] 2 [/SUP], Song Zhang[SUP] 3 [/SUP], Corey Kershaw[SUP] 1 [/SUP], Lance S Terada[SUP] 1 [/SUP], Fernando Torres[SUP] 1 [/SUP], Amit Banga[SUP] 1 [/SUP]



Affiliations

Abstract

Background: There is limited data on the predictors and outcomes of new or worsening respiratory failure among lung transplant (LT) patients with Coronavirus disease 2019 (COVID-19).
Methods: We included all the LT patients diagnosed with COVID-19 during a one-year period (March 2020 to Feb 2021; n = 54; median age: 60, 20-73 years; M:F 37:17). Development of new or worsening respiratory failure (ARF) was the primary outcome variable.
Results: The overall incidence of ARF was 48.1% (n = 26). More than 20% of patients (n = 11) needed intubation and mechanical ventilation. Body mass index >25 Kg/m[SUP]2[/SUP] (adjusted OR: 5.7, 0.99-32.93; p = 0.05) and peak D-dimer levels >0.95 mcg/mL (adjusted OR: 24.99, 1.77-353.8; p = .017) were independently associated with ARF while anticoagulation use prior to COVID-19 was protective (adjusted OR: 0.024, 0.001-0.55; p = 0.02). Majority patients survived the acute illness (85.2%). Pre-infection chronic lung allograft dysfunction (CLAD) was an independent predictor of mortality (adjusted HR: 5.03, 1.14-22.25; p = 0.033).
Conclusions: COVID-19 is associated with significant morbidity and mortality among LT patients. Patients on chronic anticoagulation seem to enjoy favorable outcomes, while higher BMI and peak D-dimer levels are associated with a higher risk of ARF. Pre-infection CLAD is associated with an increased risk of death from COVID-19. This article is protected by copyright. All rights reserved.

Keywords: D-dimer; SARS-CoV-2; allograft dysfunction; anticoagulants; coagulation; survival.
 
Back
Top Bottom